ClinicalTrials.gg
RecruitingNCT06926790GALAXY 3Updated Nov 9, 2026

Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)

A Phase 2 interventional study of Nivolumab & Ipilimumab in Lung Cancer - Non Small Cell, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 9, 2026Start date movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 43 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
59th of 120
69 · median 66
Started
2025
with 9 others
Phase 2
66 of 120
16 open now
Primary completion
2030-03
later than 36 of 42 live
Registered
109th of 120
by date

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 59th largest by planned enrollment, is one of 10 that started in 2025, is one of 66 in phase 2, reaches primary completion later than 36 of the 42 other live ones, and was the 109th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Neoadjuvant immunotherapy followed by surgery has emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, conventional chemotherapy components may increase treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1 expression \<1% remains to be improved. Emerging evidence has demonstrated that the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) provides superior responses in the treatment of advanced NSCLC. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC.

Read the detailed description

Lung cancer remains the leading cause of cancer-related death globally. Neoadjuvant immunotherapy followed by surgery has been emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). Numerous clinical trials highlighted the efficacy of preoperative immunochemotherapy, including remarkably shrinking the primary lesion, eliminating micrometastases and ultimately contributing to survival outcomes. Notably, studies also demonstrated neoadjuvant immunochemotherapy increased the access of modified surgery and enhanced survival prognosis of patients with locally advanced NSCLC (IIIB).

Despite these advances, certain limitations remain. Conventional chemotherapy components may elevate treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1\<1% remained to be improve. Emerging evidences demonstrated that nivolumab (anti-PD-1) combine with ipilimumab (antiCTLA-4) provided superior response for the treatment of advanced NSCLC patients. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC. The study will enroll 69 eligible participants, with the primary endpoint being pathological complete response (pCR) rate following neoadjuvant therapy.

03

Conditions studied

  • Lung Cancer - Non Small Cell

Keywords

  • lung cancer
  • nivolumab plus ipilimumab
  • neoadjuvant treatment
  • non-small cell lung cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. must be signed.
  2. At least 18 years of age.
  3. or cytologically confirmed non-small cell lung cancer (without EGFR, ALK mutation).
  4. Have measurable and clinical stage II-IIIA with no known expression or PD-L1 ≤ 1%.
  5. disease eligible for surgery.
  6. No previous systematic therapy or radiotherapy.
  7. (ECOG) performance status of 0 or 1.
  8. At least one .
  9. No major organ dysfunction, including liver, kidney, and cardiac function.

Exclusion criteria

Exclusion Criteria:

  1. Patients with active disease or history of autoimmune disease.
  2. Patients have received other treatment for non-small cell lung cancer or for any other .
  3. History of allergy to study drug components.
  4. Pregnant or breast-feeding.
  5. Any mental or psychological condition that would prevent the patient from completing the study or understanding the patient information.
  6. Patients who have other malignancies.
  7. History of major surgery or serious injury within the past 3 months.
  8. , , infection or active pulmonary tuberculosis.
  9. Vaccination within 4 weeks prior to the start of the study.
  10. Presence of underlying medical conditions that, in the investigator's judgment, could increase the risk associated with study drug administration or interfere with the assessment of toxicity and adverse events.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant treatment

    Patients with IIA-IIIB NSCLC will received 2-3 cycles of neoadjuvant Nivolumab (3 mg/kg intravenously (i.v.), every 3 week) plus Ipilimumab (1 mg/kg i.v., every 6 week). Surgery will be performed within 4 to 6 weeks after completion of preoperative therapy. After the second cycles treatment, contrast-enhanced chest CT will be performed to evaluate the tumor.

    Drug: Nivolumab & Ipilimumab

Interventions

  • DrugNivolumab & Ipilimumab

    Drug pages: NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This study evaluates the safety and efficacy of neoadjuvant nivolumab plus ipilimumab for IIA-IIIB NSCLC. Based on preliminary trial results, this study proposes a new treatment regimen.

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (PCR)

    Pathological complete response is predefined as no residual viable tumor cells in primary tumor and lymph nodes.

    Time frame: Within 2 weeks after surgery

Secondary outcomes

  1. 3-year Event-Free Survival (3-year EFS)

    The starting point for EFS was the initiation of neoadjuvant treatment. The endpoint for EFS was defined as the date of death, recurrence, progression, or the last follow-up.

    Time frame: From neoadjuvant treatment to the date of death, recurrence, progression, or the last follow-up (assessed up to 3 years).

  2. Major Pathological Response (MPR)

    Major pathological response defined as less than 10% of viable tumor cells in primary tumor.

    Time frame: Within 2 weeks after surgery

  3. Safety (Rate of grade 3 and higher grade treatment-related adverse events (TRAEs))

    Adverse events will be evaluated and recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).

    Time frame: Between the last dose of neoadjuvant treatment and surgery (assessed up to 30 days)

  4. Radiological Response

    Radiographic response will be evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

    Time frame: Between the last dose of neoadjuvant treatment and surgery

  5. Postoperative complications

    Postoperative complications will be evaluated and recorded after the surgery following Clavien-Dindo grade. The minimum and maximum values were grade I-V, and the higher scores mean a worse outcomes.

    Time frame: After the surgery assess to 90 days

  6. Intraoperative bleeding

    Intraoperative bleeding was assessed and recorded by the surgical team. Blood loss was estimated by measuring suction canister volume and weighing surgical sponges, subtracting irrigation fluid.

    Time frame: Up to approximately 20 weeks

  7. The Quality of Life

    The quality of life will be evaluated and recorded according to the EORTC QLQ-C30. The minimum and maximum values were 0-100, and the higher scores mean a better outcome.

    Time frame: From the Day 1 to at least 90 days after surgery

  8. Duration of surgery

    Duration of surgery is the time spent in surgery.

    Time frame: Up to approximately 20 weeks

  9. Hospital Stay

    Hospital Stay is the length of inpatient time spent in hospital.

    Time frame: Up to approximately 20 weeks

  10. Feasibility (Completion rate of neoadjuvant treatment and surgery)

    Propotion of patients who complete neoadjuvant treatment and receive surgery within 42 days after neoadjuvant treatment

    Time frame: From date of treatment allocation until surgery, assessed up to 5 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Mar 2030, 57 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 57 months is close to that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Start moved once since we started tracking on Sep 25, 2026: Feb 2025 → Jun 2025, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2025
First posted
Apr 15, 2025
StartActual
Jun 19, 2025was Feb 2025
Primary completionEst.
Mar 31, 2030
CompletionEst.
Oct 31, 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 17, 2025→Jun 19, 2025
Nov 9, 2026
Eligibility
Revised
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Start date Feb 17, 2025→Jun 19, 2025
    Eligibility Revised
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06926790
Responsible party
Shuben Li (Director, Training Program of Thoracic Surgery, Director, Section of Tracheal and Pulmonary Surgery, Thoracic Surgery Department, The First Affiliated Hospital of Guangzhou Medical University) — Principal investigator
First posted
Apr 15, 2025
Start date
Jun 19, 2025
Primary completion
Mar 31, 2030 (estimated)
Completion
Oct 31, 2030 (estimated)
Last update
Nov 9, 2026

Study contacts

Shuben Li, Professor
Contact
13500030280@163.com
020-8306-2114

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion